Brand Name

Striverdi Respimat

Generic Name
OLODATEROL Respimat
View Brand Information
FDA approval date: August 01, 2014
Classification: beta2-Adrenergic Agonist
Form: Spray

What is Striverdi Respimat (OLODATEROL Respimat)?

Living with chronic obstructive pulmonary disease (COPD) can make even simple tasks walking, climbing stairs, or carrying groceries feel exhausting. Breathing becomes a daily challenge, leaving many people struggling for air and energy. Striverdi Respimat (olodaterol Respimat) is designed to help people with COPD breathe easier, stay active, and regain confidence in their daily lives. 

Striverdi Respimat is an inhalation medication that belongs to a class of drugs known as long-acting beta₂-agonists (LABAs). These medications work by relaxing the muscles around the airways, making it easier to move air in and out of the lungs. It is used as a maintenance treatment, meaning it helps manage COPD symptoms over time, rather than providing quick relief during sudden flare-ups. Approved by the U.S. Food and Drug Administration (FDA), Striverdi Respimat offers patients long-lasting, once-daily symptom control that improves lung function and quality of life. 

What does Striverdi Respimat do? 

Striverdi Respimat is prescribed to treat chronic obstructive pulmonary disease (COPD), which includes conditions such as chronic bronchitis and emphysema. COPD causes inflammation and narrowing of the airways, leading to coughing, wheezing, shortness of breath, and fatigue. 

The medication helps by keeping airways open for a full 24 hours, making breathing easier and reducing daily symptoms. Patients often notice improved airflow, less shortness of breath, and increased ability to perform daily activities after regular use. 

Striverdi Respimat is not a rescue inhaler and should not be used to treat sudden breathing problems. Instead, it works best when used consistently every day. Clinical studies have shown that olodaterol improves lung function and reduces breathlessness compared to placebo treatments, helping patients better manage their COPD and maintain long-term respiratory stability (NIH, 2024). 

How does Striverdi Respimat work? 

Striverdi Respimat contains olodaterol, a long-acting beta₂-adrenergic agonist (LABA). In simple terms, it helps the airways in the lungs stay relaxed and open. 

Inside the lungs, the walls of the airways are surrounded by smooth muscles that can tighten due to inflammation or irritation. When this happens, airflow becomes restricted, making it difficult to breathe. Olodaterol attaches to beta₂ receptors on these airway muscles, stimulating them to relax. This relaxation widens the airways, a process known as bronchodilation allowing air to flow more freely. 

This mechanism provides long-lasting relief, helping patients breathe easier throughout the day and night. The Respimat device delivers the medication as a fine mist inhaler, ensuring deep delivery into the lungs for maximum effectiveness. Clinically, this matters because maintaining open airways helps prevent exacerbations (flare-ups), reduce hospital visits, and improve overall lung function over time. 

Striverdi Respimat side effects 

Like all medications, Striverdi Respimat can cause side effects. Most are mild and temporary, but it’s important to be aware of them. 

Common side effects may include: 

  • Cough or mild throat irritation 
     
  • Dizziness or headache 
     
  • Nasal congestion or sore throat 
     
  • Muscle cramps 
     
  • Joint or back pain 

Serious side effects (less common): 

  • Chest pain or rapid heartbeat 
     
  • Severe dizziness or fainting 
     
  • Worsening breathing problems right after use 
     
  • Signs of allergic reaction such as rash, swelling, or difficulty breathing 

Because Striverdi Respimat is a LABA, it should not be used as monotherapy for asthma, as this could increase the risk of asthma-related complications. However, it is safe and well-studied for COPD when used as directed. 

People with heart conditions, high blood pressure, thyroid disorders, diabetes, or seizures should inform their doctor before starting the medication. Patients should seek immediate medical attention if they experience severe chest pain, irregular heartbeat, or sudden worsening of breathing. 

Overall, most patients tolerate Striverdi Respimat well. Regular follow-up visits help ensure any side effects are identified and managed early. 

Striverdi Respimat dosage 

Striverdi Respimat is inhaled once daily at the same time for 24-hour airway opening. The slow mist aids deep inhalation, especially for those with reduced lung capacity. Follow healthcare provider instructions for proper use; do not exceed the dose or combine with other long-acting beta₂-agonists due to side effect risks. 

Doctors may recommend periodic lung function tests and blood pressure monitoring to ensure the medication remains effective and well-tolerated. For older adults or those with underlying heart conditions, dosage adjustments are usually not necessary, but careful monitoring is advised. 

Does Striverdi Respimat have a generic version? 

As of 2025, Striverdi Respimat (olodaterol Respimat) does not currently have a generic version approved in the United States. It is available only as the brand-name product manufactured by Boehringer Ingelheim Pharmaceuticals. 

Olodaterol is also in Stiolto Respimat with tiotropium for broader symptom control. A generic Striverdi Respimat will have the same active ingredient, strength, safety, and effectiveness. Patients can discuss cost with their healthcare provider. 

Conclusion 

Striverdi Respimat is a trusted, once-daily inhalation therapy for adults living with COPD. By relaxing airway muscles and improving airflow, it helps people breathe more easily and enjoy greater independence in daily life. 

Striverdi Respimat is vital for long-term COPD management, reducing symptoms, preventing flare-ups, and improving lung function. Most patients experience better breathing and quality of life with proper use and medical supervision. Openly communicate with your doctor about its role in your care, side effects, and follow-up. This medication can significantly boost your confidence in living and breathing. 

References 

  1. U.S. Food and Drug Administration (FDA). (2024). Striverdi Respimat (olodaterol) prescribing information. Retrieved from https://www.accessdata.fda.gov 
     
  1. Mayo Clinic. (2024). Olodaterol (inhalation route) drug information. Retrieved from https://www.mayoclinic.org 
     
  1. MedlinePlus. (2024). Olodaterol inhalation: Uses, side effects, and precautions. National Library of Medicine. Retrieved from https://medlineplus.gov 
     
  1. National Institutes of Health (NIH). (2024). Long-acting bronchodilators in COPD management. Retrieved from https://www.nih.gov 
     

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Drugs for COPD.
Expanded table: Correct use of inhalers for asthma.

Brand Information

Striverdi Respimat (olodaterol respimat inhalation spray)
1DOSAGE AND ADMINISTRATION
The recommended dosage of STRIVERDI RESPIMAT is two inhalations once-daily at the same time of the day. Do not use STRIVERDI RESPIMAT more than two inhalations every 24 hours.
Prior to first use, the STRIVERDI RESPIMAT cartridge is inserted into the STRIVERDI RESPIMAT inhaler and the unit is primed. When using the unit for the first time, patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use. If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use
No dosage adjustment is required for geriatric patients, patients with mild and moderate hepatic impairment, or renally-impaired patients. There are no data available for use of STRIVERDI RESPIMAT in severe hepatically impaired patients
2DOSAGE FORMS AND STRENGTHS
STRIVERDI RESPIMAT consists of a STRIVERDI RESPIMAT inhaler and an aluminum cylinder (STRIVERDI RESPIMAT cartridge) containing olodaterol (as the hydrochloride). The STRIVERDI RESPIMAT cartridge is intended for use with the STRIVERDI RESPIMAT inhaler only.
Each actuation from the STRIVERDI RESPIMAT inhaler delivers 2.5 mcg olodaterol (equivalent to 2.736 mcg olodaterol hydrochloride) from the mouthpiece. Two actuations equal one dose.
3CONTRAINDICATIONS
Use of a LABA, including STRIVERDI RESPIMAT, without an inhaled corticosteroid is contraindicated in patients with asthma
4ADVERSE REACTIONS
Long-acting beta
4.1Clinical Trials Experience in Chronic Obstructive Pulmonary Disease
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The STRIVERDI RESPIMAT clinical development program included seven dose-ranging trials and eight confirmatory trials. Four of the confirmatory trials were 6-week cross-over trials and four were 48-week parallel group trials. Adverse reactions observed in the dose-ranging trials and four 6-week cross-over trials were consistent with those observed in the 48-week parallel group trials, which formed the primary safety database.
The primary safety database consisted of pooled data from the four 48-week double-blind, active and placebo-controlled, parallel group confirmatory clinical trials. These trials included 3,104 adult COPD patients (77% males and 23% females) 40 years of age and older. Of these patients, 876 and 883 patients were treated with STRIVERDI RESPIMAT 5 mcg and 10 mcg once-daily, respectively. The STRIVERDI RESPIMAT groups were composed of mostly Caucasians (66%) with a mean age of 64 years and a mean percent predicted FEV
In these four clinical trials, seventy-two percent (72%) of patients exposed to any dose of STRIVERDI RESPIMAT reported an adverse reaction compared to 71% in the placebo group. The proportion of patients who discontinued due to an adverse reaction was 7.2% for STRIVERDI RESPIMAT treated patients compared to 8.8% for placebo treated patients. The adverse reaction most commonly leading to discontinuation was worsening COPD. The most common serious adverse reactions were COPD exacerbation, pneumonia, and atrial fibrillation.
Table 1 shows all adverse drug reactions reported by at least 2% of patients (and higher than placebo) who received STRIVERDI RESPIMAT 5 mcg during the 48-week trials.
Additional adverse reactions that occurred in greater than 2% (and higher than placebo) of patients exposed to STRIVERDI RESPIMAT 10 mcg were pneumonia, constipation, and pyrexia.
Lung cancers were reported in 6 (0.7%), 3 (0.3%), and 2 (0.2%) patients who received STRIVERDI RESPIMAT 10 mcg, 5 mcg, and placebo, respectively.
5OVERDOSAGE
The expected signs and symptoms with overdosage of STRIVERDI RESPIMAT are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., myocardial ischemia, angina pectoris, hypertension or hypotension, tachycardia, arrhythmias, palpitations, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasms, nausea, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of STRIVERDI RESPIMAT.
Treatment of overdosage consists of discontinuation of STRIVERDI RESPIMAT together with institution of appropriate symptomatic and supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of STRIVERDI RESPIMAT. Cardiac monitoring is recommended in cases of overdosage.
6DESCRIPTION
The active moiety olodaterol is a selective beta
The structural formula is:
Chemical Structure
The drug product, STRIVERDI RESPIMAT, is composed of a sterile, aqueous solution of olodaterol hydrochloride filled into a 4.5 mL plastic container crimped into an aluminum cylinder (STRIVERDI RESPIMAT cartridge) for use with the STRIVERDI RESPIMAT inhaler.
Excipients include anhydrous citric acid, benzalkonium chloride, edetate disodium, and water for injection. The STRIVERDI RESPIMAT cartridge is only intended for use with the STRIVERDI RESPIMAT inhaler. The STRIVERDI RESPIMAT inhaler is a hand held, pocket sized oral inhalation device that uses mechanical energy to generate a slow-moving aerosol cloud of medication from a metered volume of the drug solution. The STRIVERDI RESPIMAT inhaler has a yellow-colored cap.
When used with the STRIVERDI RESPIMAT inhaler, each cartridge containing a minimum of 4 grams of a sterile aqueous solution delivers the labeled number of metered actuations after preparation for use. Each dose (one dose equals two actuations) from the STRIVERDI RESPIMAT inhaler delivers 5 mcg olodaterol (equivalent to 5.473 mcg olodaterol hydrochloride) in 22.1 mcL of solution from the mouthpiece. As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as the coordination between the actuation of the inhaler and inspiration through the delivery system. The duration of inspiration should be at least as long as the spray duration (1.5 seconds).
Prior to first use, the STRIVERDI RESPIMAT cartridge is inserted into the STRIVERDI RESPIMAT inhaler and the unit is primed. When using for the first time, patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use. If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use
7CLINICAL STUDIES
The STRIVERDI RESPIMAT clinical development program included three dose-ranging trials in COPD patients, four dose-ranging trials in asthma patients, and eight confirmatory trials in patients with COPD.
8HOW SUPPLIED/STORAGE AND HANDLING
STRIVERDI RESPIMAT Inhalation Spray is supplied in a labeled carton containing one STRIVERDI RESPIMAT cartridge and one STRIVERDI RESPIMAT inhaler.
The STRIVERDI RESPIMAT cartridge is an aluminum cylinder with a tamper protection seal on the cap. The STRIVERDI RESPIMAT cartridge is only intended for use with the STRIVERDI RESPIMAT inhaler.
The STRIVERDI RESPIMAT inhaler is a cylindrical-shaped plastic inhalation device with a gray-colored body and a clear base. The clear base is removed to insert the cartridge. The inhaler contains a dose indicator. The yellow colored cap and the written information on the label of the gray inhaler body indicates that it is labeled for use with the STRIVERDI RESPIMAT cartridge.
STRIVERDI RESPIMAT Inhalation Spray is available as:
STRIVERDI RESPIMAT Inhalation Spray: 60 metered actuations (NDC 0597-0192-61)
The STRIVERDI RESPIMAT cartridge has a net fill weight of at least 4 grams and when used with the STRIVERDI RESPIMAT inhaler, is designed to deliver the labeled number of metered actuations after preparation for use.
When the labeled number of metered actuations has been dispensed from the inhaler, the STRIVERDI RESPIMAT locking mechanism will be engaged and no more actuations can be dispensed.
After assembly, the STRIVERDI RESPIMAT inhaler should be discarded at the latest 3 months after first use or when the locking mechanism is engaged, whichever comes first.
Keep out of reach of children. Do not spray into eyes.
9PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
10Instructions for Use
STRIVERDI (STRIH ver dee- RES peh mat)
(olodaterol inhalation spray), for oral inhalation use
For Oral Inhalation Only
Do not spray STRIVERDI RESPIMAT into your eyes.
Read these Instructions for Use before you start using STRIVERDI RESPIMAT and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.
You will need to use this inhaler 1 time each day, at the same time each day. Each time you use it take 2 puffs.
Do not turn the clear base before inserting the cartridge.
Image
How to store your STRIVERDI RESPIMAT inhaler
  • Store STRIVERDI RESPIMAT at room temperature between 68°F to 77°F (20°C to 25°C).
  • Do not freeze your STRIVERDI RESPIMAT cartridge and inhaler.
  • If STRIVERDI RESPIMAT has not been used for more than 3 days, release 1 puff towards the ground.
  • If STRIVERDI RESPIMAT has not been used for more than 21 days, repeat steps 4 to 6 under the "Prepare for first use" until a mist is visible. Then repeat steps 4 to 6 three more times.
  • Keep your STRIVERDI RESPIMAT cartridge and inhaler out of the reach of children.
How to care for your STRIVERDI RESPIMAT inhaler
Clean the mouthpiece, including the metal part inside the mouthpiece, with a damp cloth or tissue only, at least once a week. Any minor discoloration in the mouthpiece does not affect your STRIVERDI RESPIMAT inhaler.
When to get a new STRIVERDI RESPIMAT inhaler
  • Your inhaler contains 60 puffs (30 doses) if used as indicated (2 puffs once daily). If you have a sample, your inhaler contains 28 puffs (14 doses) if used as indicated (2 puffs once daily).
  • The dose indicator shows approximately how much medicine is left.
  • When the dose indicator enters the red area of the scale you need to get a refill; there is approximately medicine for 7 days left (if you have a sample, there is approximately medicine for 3 days left).
  • When the dose indicator reaches the end of the red scale, your STRIVERDI RESPIMAT is empty and automatically locks. At this point, the clear base cannot be turned any further.
  • Three months after insertion of cartridge, throw away the STRIVERDI RESPIMAT even if it has not been used, or when the inhaler is locked, or when it expires, whichever comes first.
Prepare for first use
Daily use (
Answers to Common Questions
It is difficult to insert the cartridge deep enough:
Did you accidentally turn the clear base before inserting the cartridge? Open the cap, press the dose-release button, then insert the cartridge.
Did you insert the cartridge with the wide end first? Insert the cartridge with the narrow end first.
I cannot press the dose-release button:
Did you turn the clear base? If not, turn the clear base in a continuous movement until it clicks (half a turn).
Is the dose indicator on the STRIVERDI RESPIMAT pointing to zero? The STRIVERDI RESPIMAT inhaler is locked after 60 puffs (30 doses). If you have a sample, the STRIVERDI RESPIMAT inhaler is locked after 28 puffs (14 doses). Prepare and use your new STRIVERDI RESPIMAT inhaler.
I cannot turn the clear base:
Did you turn the clear base already? If the clear base has already been turned, follow steps "Open" and "Press" under "Daily use" to get your medicine.
Is the dose indicator on the STRIVERDI RESPIMAT pointing to zero? The STRIVERDI RESPIMAT inhaler is locked after 60 puffs (30 doses). If you have a sample, the STRIVERDI RESPIMAT inhaler is locked after 28 puffs (14 doses). Prepare and use your new STRIVERDI RESPIMAT inhaler.
The dose indicator on the STRIVERDI RESPIMAT reaches zero too soon:
Did you use STRIVERDI RESPIMAT as indicated (2 puffs once daily)? STRIVERDI RESPIMAT will deliver 60 puffs and last 30 days if used at 2 puffs once daily. If you have a sample, STRIVERDI RESPIMAT will deliver 28 puffs and last 14 days if used at 2 puffs once daily.
Did you turn the clear base before you inserted the cartridge? The dose indicator counts each turn of the clear base regardless whether a cartridge has been inserted or not.
Did you spray in the air often to check whether the STRIVERDI RESPIMAT is working? Once you have prepared STRIVERDI RESPIMAT, no test-spraying is required if used daily.
Did you insert the cartridge into a used STRIVERDI RESPIMAT? Always insert a new cartridge into a NEW STRIVERDI RESPIMAT.
My STRIVERDI RESPIMAT sprays automatically:
Was the cap open when you turned the clear base? Close the cap, then turn the clear base.
Did you press the dose-release button when turning the clear base? Close the cap, so the dose-release button is covered, then turn the clear base.
Did you stop when turning the clear base before it clicked? Turn the clear base in a continuous movement until it clicks (half a turn).
My STRIVERDI RESPIMAT doesn't spray:
Did you insert a cartridge? If not, insert a cartridge.
Did you repeat Turn, Open, Press (TOP) less than three times after inserting the cartridge? Repeat Turn, Open, Press (TOP) three times after inserting the cartridge as shown in steps 4 to 6 under "Prepare for first use".
Is the dose indicator on the STRIVERDI RESPIMAT pointing to 0? You have used up all your medicine and the inhaler is locked.
This product's label may have been updated. For current full prescribing information for STRIVERDI RESPIMAT, go to
Image
This Patient Information and Instructions for Use has been approved by the U.S. Food and Drug Administration.
Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA
Licensed from: Boehringer Ingelheim International GmbH
STRIVERDI
Copyright © 2025 Boehringer Ingelheim International GmbH
Revised: January 2025
COL10540BA022025
11PRINCIPAL DISPLAY PANEL - 2.5 mcg Cartridge Carton
NDC 0597-0192-61
2.5 mcg/actuation*
FOR ORAL INHALATION ONLY
ATTENTION PHARMACIST:
Rx only
4 Grams
Boehringer
PRINCIPAL DISPLAY PANEL - 2.5 mcg Cartridge Carton